Auph short interest.

If you stay in your home long enough, you usually build enough equity that you can sell it for a profit. When you have to sell the property before then or during a downturn in the market, you may need to find out how to short sale a house.AUPH: Aurinia favored at Cantor despite earnings miss • 2:25 PM. Aurinia Pharmaceuticals (AUPH -18.2%) has plunged after the company’s Q1 financials came below expectations.Short Interest. Most Shorted. Largest Increase. Largest Decrease. ... The analyst firm set a price target for $15.00 expecting AUPH to rise to within 12 months (a possible 67.41% upside).In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...About Aurinia Pharmaceuticals Stock (TSE:AUP) Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license ...

Nov 24, 2023 · View real-time AUPH stock price and news, along with industry-best analysis. Explore Our Brands. WSJ; ... Short Interest Change-0.88%: Percent of Float: 13.23%: Advanced $ 1D. Compare. Peers. Name ... Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

AuriniaPharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 12,670,00WebAffimed saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,640,000 shares, a decline of 24.1% from the October 31st total of 2,160,000 shares. Based on an average daily volume of 562,700 shares, the short-interest ratio is currently 2.9 days. View Affimed's Short Interest.

Short Interest Change. -0.88%. Percent of Float. 13.23%. Overview. Complete Aurinia Pharmaceuticals Inc. stock information by Barron's. View real-time AUPH stock price and news, along with...Mar 23, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville ... For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...Analyst’s Disclosure: I/we have a beneficial long position in the shares of AUPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

This page provides short interest, short volume, short volume ratio, short borrow rates, and short squeeze score for the security. US: AUPH / Aurinia Pharmaceuticals Inc - Insider Trading Report This page provides data on the corporate insiders of Aurinia Pharmaceuticals Inc and their trades, trade performance, and predictive analysis.

Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past year. Passive investing in index funds can generate returns that roughly …AUPH: Aurinia favored at Cantor despite earnings miss • 2:25 PM. Aurinia Pharmaceuticals (AUPH -18.2%) has plunged after the company’s Q1 financials came below expectations.Jul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ... Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ... Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...The average one-year price target for AUPH / Aurinia Pharmaceuticals Inc is $14.28. The forecasts range from a low of $12.12 to a high of $15.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond ...Despite upbeat remarks from its chief executive ahead of the earnings, Aurinia’s (NASDAQ:AUPH) 2022 sales guidance fell short of expectations as net revenue for the year dropped ~9% YoY to $45 ...

Affimed saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,640,000 shares, a decline of 24.1% from the October 31st total of 2,160,000 shares. Based on an average daily volume of 562,700 shares, the short-interest ratio is currently 2.9 days. View Affimed's Short Interest.Sep 30, 2023 · Net amortization of premiums and discounts on short-term investments (8,836) (14) Share-based compensation expense: 33,543 25,398 Write-down of inventory: 916 2,464 Other, net (3,910) 601 Net changes in operating assets and liabilities: Accounts receivable, net (24,463) (26,356) Inventories, net (8,984) (8,458) Prepaid expenses and other ... AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals.The forecasted annual EBITDA of AUPH / Aurinia Pharmaceuticals Inc in 2025-12-31 is -52MM. EBIDTA is an acronym that stands for earnings before interest, taxes, depreciation, and amortization. Analysts and investors pay attention to EBITDA because it strips out items that a company must report on its balance sheet but doesn’t significantly ...

Short Interest Change. -0.88%. Percent of Float. 13.23%. Overview. Complete Aurinia Pharmaceuticals Inc. stock information by Barron's. View real-time AUPH stock price and news, along with...

Aurinia Pharmaceuticals Stock (NASDAQ:AUPH), Short Interest Report. Short interest for Aurinia Pharmaceuticals gives investors a sense of the degree to …Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.08 beats by $0.11. Revenue of $41.49M (+47.2% Y/Y) beats by $3.98M. Increases 2023 revenue guidance range to $150 - $160 million ...Dec 10, 2021 · Aurinia Pharmaceuticals (NASDAQ: AUPH) is trading ~2.5% higher in the pre-market after Oppenheimer raised its recommendation on the stock to Outperform from Perform. The price target of $31 per ... About Aurinia Pharmaceuticals Stock (TSE:AUP) Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license ...AUPH has no debt and, even better, 400 millions in cash. Good market penetration so far (100 patients Q1, 400 Q2) and guidance provided for the end of the year (40-50 millions) with great expectations for the next years (200 in 2022, 400 in 2023, sales peak at 1.5 billions) ... The short interest. Since the FDA Approval in Jan 2021, the stock ...Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on...

Get the latest SCYNEXIS Inc (SCYX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

AUPH opened at $9.06 on Friday. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.07 and a 1 year high of $12.43. The stock’s 50 day simple moving average is $7.93 and its 200 day simple ...

Aurinia Pharmaceuticals (AUPH +4.4%) is trading higher after its Chief Executive Officer Peter Greenleaf hinted at strong sales for the company as the management prepares to release the financials ...Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of FloatAurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze.com.In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...Oct 29, 2021 · Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ... Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin ...Which Aurinia Pharmaceuticals insiders have been selling company stock? The following insiders have sold AUPH shares in the last 24 months: David R.W. Jayne ($98,333.58), Joseph M Miller ($100,986.24), Joseph P Hagan ($2,877.76), Peter Greenleaf ($292,785.00), and Stephen P Robertson ($173,453.88). How much insider selling is …

30 Mar 2023 ... ... AUPH stock is predictable in the short/long term. According to price ... If an entity originates a loan that bears an off-market interest ...Aurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...Shares of Aurinia Pharmaceuticals (AUPH) have gained 13.7% over the past four weeks to close the last trading session at $8.29, but there could still be a solid upside left in the stock if short ...WebShort Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...Instagram:https://instagram. wealth management namesbest trading books for beginnersk.s.c.potcmkts shmp A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short. With the short side of the trade heavily crowded, and a few shares publicly ...Dec 1, 2023 · The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents. joker watchamp token The setup was perfect (IMO) with more than 21% Short Interest, a Put/Call ratio of 0.25 (Dec-2023) and a strong earnings + guidance from a grossly oversold position. Long term Bullish, but I will be waiting for the $3.29 gap fill most likely to re-build, unless the Company can formalize a plan to be NASDAQ compliant in short-order. 1969: CARV top property investors Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Short Squeeze Ranking™. view. Daily Short Sale Volume. view. Short Interest (Shares Short) Author: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…View the latest Aurinia Pharmaceuticals Inc. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.